Skin cancers are the most common groups of cancers diagnosed worldwide.
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.
Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.
Meet our team of experts dedicated to pioneering breakthroughs in therapeutics. Their unparalleled expertise & passion drive our mission to transform dermatology
Meet our team of experts dedicated to pioneering breakthroughs in therapeutics. Their unparalleled expertise & passion drive our mission to transform dermatology
BO-112 monotherapy
A Multicenter, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High-Risk Basal Cell Carcinoma.
Independent
